Allergan Plc (AGN) 243.43 $AGN
5 Biotech Stocks to Watch as Interest in NASH Increases
Arpita Dutt - Zacks Investment Research - Thu Sep 22, 8:08AM CDT
The fact that Allergan (AGN) is willing to shell out as much as up to $1.695 billion for Tobira has led to speculation that more acquisition deals will be announced in this space.
AGN: 243.43 (+5.02), GLMD: 5.50 (+0.86), CNAT: 2.16 (+0.06), GALT: 2.87 (+0.27), ICPT: 170.47 (+1.69), ENTA: 26.60 (-0.21)
Biotechnology Companies Reaching New Milestones
PR Newswire - Thu Sep 22, 8:00AM CDT
Transparency Market Research published a report on the global biotechnology market and claiming that this vibrant market is expected to grow at an average annual growth rate of CAGR rate of 11.6% by the end of 2017. The data provided indicates that in 2011, the market was valued at roughly $216.5 billion, yet major changes in the way the industry operates and innovative developments in the sector, have pushed values to reach $414.5 billion by the end of 2017. Allergan PLC (NYSE: AGN), Tobira Therapeutics, Inc. (NASDAQ: TBRA), MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), Aerie Pharmaceuticals Inc. (NASDAQ: AERI), Puma Biotechnology Inc. (NYSE: PBYI).
AGN: 243.43 (+5.02), MBVX: 4.76 (+0.01), AERI: 38.05 (-0.80), TBRA: 39.50 (+0.42), PBYI: 65.98 (-1.99)
Allergan and Adamas Announce U.S. Availability of New Dosage Strengths for NAMZARIC® (Memantine and Donepezil Hydrochlorides) Extended Release for the Treatment of Moderate to Severe Alzheimer's Disease
PR Newswire - Thu Sep 22, 7:00AM CDT
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced today that all four dosage strengths of NAMZARIC® (memantine and donepezil hydrochlorides) extended-release capsules that allow patients on donepezil 10 mg to start directly on NAMZARIC are now available by prescription in pharmacies throughout the U.S. NAMZARIC is a once-daily, fixed-dose combination of memantine hydrochloride (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor, AChEI) for the treatment of moderate to severe Alzheimer's Disease in patients stabilized on 10 mg of donepezil hydrochloride once daily. NAMZARIC'S new indication and dosage strengths were approved by the U.S. Food and Drug Administration (FDA) in July 2016.
AGN: 243.43 (+5.02), ADMS: 18.07 (+0.26)
Is Galectin The Next Takeover Target for the Biotech World?
Zacks Equity Research - Zacks Investment Research - Thu Sep 22, 4:53AM CDT
It is being speculated that Galectin could be the next takeover target in the biotech world after Allergan plc's (AGN) highly expensive definitive deal to acquire Tobira Therapeutics, Inc. (TBRA) was announced on Tuesday.
AGN: 243.43 (+5.02), GILD: 81.52 (-0.18), GALT: 2.87 (+0.27), TBRA: 39.50 (+0.42)
Allergan M&A News Could Heat Up Small Biotechs
ACCESSWIRE - Wed Sep 21, 1:30PM CDT
LAS VEGAS, NV / ACCESSWIRE / September 21, 2016 / After a year of losses in the biotech sector, things are heating right back up on large buy-outs of high-risk companies. Large pharmaceutical companies are beginning to go a spending spree, shifting away from established medicines and toward much higher risk-reward projects in order to transform and produce outsized growth.
AGN: 243.43 (+5.02), SKLN: 0.18 (unch), TBRA: 39.50 (+0.42)
Biotech ETFs in Focus on Tobira Therapeutics' Massive Gain
Sanghamitra Saha - Zacks Investment Research - Wed Sep 21, 10:23AM CDT
Tobira Therapeutics surged following the news that Allergan is buying it at an astounding premium and drove several biotech ETFs higher.
BBP: 34.62 (+0.44), AGN: 243.43 (+5.02), SBIO: 27.22 (+0.06), BBC: 23.12 (+0.24), GLMD: 5.50 (+0.86), XBI: 68.83 (+0.55), CNAT: 2.16 (+0.06), ICPT: 170.47 (+1.69), IBB: 300.08 (+2.55)
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Tobira Therapeutics, Inc. to Allergan plc for $28.35 Per Share Is Fair to Shareholders
BusinessWire - Wed Sep 21, 10:11AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
AGN: 243.43 (+5.02), TBRA: 39.50 (+0.42)
Harwood Feffer LLP Announces Investigation of Tobira Therapeutics, Inc.
PR Newswire - Wed Sep 21, 9:31AM CDT
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Tobira Therapeutics, Inc. ("Tobira" or the "Company"
(NASDAQ: TBRA) concerning the proposed acquisition of the Company by Allergan Plc ("Allergan".
AGN: 243.43 (+5.02), TBRA: 39.50 (+0.42)
Stock Market News for September 21, 2016
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 9:22AM CDT
Benchmarks finished slightly higher on Tuesday ahead of the two-day policy meetings of the Fed and Bank of Japan (BOJ) ending today
FDX: 173.66 (-0.20), AGN: 243.43 (+5.02), PBR: 9.56 (+0.05), BIIB: 314.81 (+2.81), SON: 53.50 (+0.46), GILD: 81.52 (-0.18), FB: 130.08 (+0.14), XOM: 83.54 (+0.24), AMGN: 175.62 (+1.77), KBH: 15.65 (+0.42), TBRA: 39.50 (+0.42)
Allergan Buys NASH Therapy Maker Tobira at Huge Premium
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 5:55AM CDT
Allergan plc (AGN) announced a definitive deal to acquire Tobira Therapeutics, Inc. (TBRA) for a total potential consideration of around $1.7 billion.
AGN: 243.43 (+5.02), GILD: 81.52 (-0.18), ICPT: 170.47 (+1.69), TBRA: 39.50 (+0.42)
Asian shares mixed as Bank of Japan, Fed mull policy options
By ELAINE KURTENBACH - AP - Tue Sep 20, 10:06PM CDT
TOKYO (AP) — Asian shares meandered Wednesday as markets awaited the outcomes of monetary policy meetings in the U.S. and Japan. Japan's benchmark fell after August trade data came in weaker than expected.
AGN: 243.43 (+5.02), RCL: 70.99 (+3.13)
Allergan targets liver disease drugs with Tobira acquisition
By The Associated Press - AP - Tue Sep 20, 5:45PM CDT
Botox-maker Allergan is bulking up its drug pipeline with two acquisitions announced Tuesday, both of which target liver disease.
AGN: 243.43 (+5.02), TBRA: 39.50 (+0.42)
Tobira, Royal Caribbean and Marriott rise; Ascena dives
AP - Tue Sep 20, 4:49PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
AGN: 243.43 (+5.02), GE: 30.04 (+0.19), LEN: 43.60 (+0.15), RCL: 70.99 (+3.13), PIR: 4.26 (+0.16), ASNA: 5.91 (+0.34), LEN.B: 34.80 (+0.20), MAR: 69.75 (-0.39), TBRA: 39.50 (+0.42)
Business Highlights
By The Associated Press - AP - Tue Sep 20, 4:17PM CDT
___
AGN: 243.43 (+5.02), FDX: 173.66 (-0.20), MON: 104.20 (-0.16), MYL: 42.59 (+0.68), M: 36.26 (+0.25), WFC: 45.72 (-0.11), TBRA: 39.50 (+0.42)
Why Did Tobira Therapeutics (TBRA) Stock Skyrocket 720% Today?
Madeleine Johnson - Zacks Investment Research - Tue Sep 20, 3:49PM CDT
On Tuesday, shares of Tobira Therapeutics Inc. (TBRA) skyrocketed, up over 720% in late-afternoon trading after the company announced it would be acquired by Allergan (AGN) in a deal worth up to $1.7 billion.
AGN: 243.43 (+5.02), TBRA: 39.50 (+0.42)
Akarna Therapeutics Ltd acquired by Allergan plc
BusinessWire - Tue Sep 20, 3:23PM CDT
Akarna Therapeutics Ltd., a privately held biopharmaceutical company, announced today that it has been acquired by Allergan plc. Allergan obtains rights to AKN-083, Akarna's lead product candidate for the potential treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases.
AGN: 243.43 (+5.02)
Allergan Acquires Akarna Therapeutics Adding to its Strong Development Program and Commitment to Innovation in NASH
PR Newswire - Tue Sep 20, 3:15PM CDT
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the Company has acquired Akarna Therapeutics Ltd., a privately held biopharmaceutical company focused on developing novel small molecule therapeutics that target inflammatory and fibrotic diseases, for an up-front payment of $50 million, subject to certain adjustments, as well as potential clinical, regulatory and commercial milestone payments related to its lead development compound, AKN-083. In addition to AKN-083, the acquisition also includes a portfolio of additional development-stage FXR compounds.
AGN: 243.43 (+5.02), TBRA: 39.50 (+0.42)
Watch for Allergan to Potentially Rebound After Falling 2.40% Yesterday
Comtex SmarTrend(R) - Tue Sep 20, 11:45AM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $237.85 to a high of $243.94. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $243.72 on volume of 3.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 243.43 (+5.02)
TOBIRA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
BusinessWire - Tue Sep 20, 10:43AM CDT
Rigrodsky & Long, P.A.:
AGN: 243.43 (+5.02), TBRA: 39.50 (+0.42)
5 Biotech Stocks to Watch as Interest in NASH Increases
Arpita Dutt - Zacks Investment Research - Thu Sep 22, 8:08AM CDT
The fact that Allergan (AGN) is willing to shell out as much as up to $1.695 billion for Tobira has led to speculation that more acquisition deals will be announced in this space.
AGN: 243.43 (+5.02), GLMD: 5.50 (+0.86), CNAT: 2.16 (+0.06), GALT: 2.87 (+0.27), ICPT: 170.47 (+1.69), ENTA: 26.60 (-0.21)
Biotechnology Companies Reaching New Milestones
PR Newswire - Thu Sep 22, 8:00AM CDT
Transparency Market Research published a report on the global biotechnology market and claiming that this vibrant market is expected to grow at an average annual growth rate of CAGR rate of 11.6% by the end of 2017. The data provided indicates that in 2011, the market was valued at roughly $216.5 billion, yet major changes in the way the industry operates and innovative developments in the sector, have pushed values to reach $414.5 billion by the end of 2017. Allergan PLC (NYSE: AGN), Tobira Therapeutics, Inc. (NASDAQ: TBRA), MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), Aerie Pharmaceuticals Inc. (NASDAQ: AERI), Puma Biotechnology Inc. (NYSE: PBYI).
AGN: 243.43 (+5.02), MBVX: 4.76 (+0.01), AERI: 38.05 (-0.80), TBRA: 39.50 (+0.42), PBYI: 65.98 (-1.99)
Allergan and Adamas Announce U.S. Availability of New Dosage Strengths for NAMZARIC® (Memantine and Donepezil Hydrochlorides) Extended Release for the Treatment of Moderate to Severe Alzheimer's Disease
PR Newswire - Thu Sep 22, 7:00AM CDT
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced today that all four dosage strengths of NAMZARIC® (memantine and donepezil hydrochlorides) extended-release capsules that allow patients on donepezil 10 mg to start directly on NAMZARIC are now available by prescription in pharmacies throughout the U.S. NAMZARIC is a once-daily, fixed-dose combination of memantine hydrochloride (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor, AChEI) for the treatment of moderate to severe Alzheimer's Disease in patients stabilized on 10 mg of donepezil hydrochloride once daily. NAMZARIC'S new indication and dosage strengths were approved by the U.S. Food and Drug Administration (FDA) in July 2016.
AGN: 243.43 (+5.02), ADMS: 18.07 (+0.26)
Is Galectin The Next Takeover Target for the Biotech World?
Zacks Equity Research - Zacks Investment Research - Thu Sep 22, 4:53AM CDT
It is being speculated that Galectin could be the next takeover target in the biotech world after Allergan plc's (AGN) highly expensive definitive deal to acquire Tobira Therapeutics, Inc. (TBRA) was announced on Tuesday.
AGN: 243.43 (+5.02), GILD: 81.52 (-0.18), GALT: 2.87 (+0.27), TBRA: 39.50 (+0.42)
Allergan M&A News Could Heat Up Small Biotechs
ACCESSWIRE - Wed Sep 21, 1:30PM CDT
LAS VEGAS, NV / ACCESSWIRE / September 21, 2016 / After a year of losses in the biotech sector, things are heating right back up on large buy-outs of high-risk companies. Large pharmaceutical companies are beginning to go a spending spree, shifting away from established medicines and toward much higher risk-reward projects in order to transform and produce outsized growth.
AGN: 243.43 (+5.02), SKLN: 0.18 (unch), TBRA: 39.50 (+0.42)
Biotech ETFs in Focus on Tobira Therapeutics' Massive Gain
Sanghamitra Saha - Zacks Investment Research - Wed Sep 21, 10:23AM CDT
Tobira Therapeutics surged following the news that Allergan is buying it at an astounding premium and drove several biotech ETFs higher.
BBP: 34.62 (+0.44), AGN: 243.43 (+5.02), SBIO: 27.22 (+0.06), BBC: 23.12 (+0.24), GLMD: 5.50 (+0.86), XBI: 68.83 (+0.55), CNAT: 2.16 (+0.06), ICPT: 170.47 (+1.69), IBB: 300.08 (+2.55)
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Tobira Therapeutics, Inc. to Allergan plc for $28.35 Per Share Is Fair to Shareholders
BusinessWire - Wed Sep 21, 10:11AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
AGN: 243.43 (+5.02), TBRA: 39.50 (+0.42)
Harwood Feffer LLP Announces Investigation of Tobira Therapeutics, Inc.
PR Newswire - Wed Sep 21, 9:31AM CDT
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Tobira Therapeutics, Inc. ("Tobira" or the "Company"
(NASDAQ: TBRA) concerning the proposed acquisition of the Company by Allergan Plc ("Allergan". AGN: 243.43 (+5.02), TBRA: 39.50 (+0.42)
Stock Market News for September 21, 2016
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 9:22AM CDT
Benchmarks finished slightly higher on Tuesday ahead of the two-day policy meetings of the Fed and Bank of Japan (BOJ) ending today
FDX: 173.66 (-0.20), AGN: 243.43 (+5.02), PBR: 9.56 (+0.05), BIIB: 314.81 (+2.81), SON: 53.50 (+0.46), GILD: 81.52 (-0.18), FB: 130.08 (+0.14), XOM: 83.54 (+0.24), AMGN: 175.62 (+1.77), KBH: 15.65 (+0.42), TBRA: 39.50 (+0.42)
Allergan Buys NASH Therapy Maker Tobira at Huge Premium
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 5:55AM CDT
Allergan plc (AGN) announced a definitive deal to acquire Tobira Therapeutics, Inc. (TBRA) for a total potential consideration of around $1.7 billion.
AGN: 243.43 (+5.02), GILD: 81.52 (-0.18), ICPT: 170.47 (+1.69), TBRA: 39.50 (+0.42)
Asian shares mixed as Bank of Japan, Fed mull policy options
By ELAINE KURTENBACH - AP - Tue Sep 20, 10:06PM CDT
TOKYO (AP) — Asian shares meandered Wednesday as markets awaited the outcomes of monetary policy meetings in the U.S. and Japan. Japan's benchmark fell after August trade data came in weaker than expected.
AGN: 243.43 (+5.02), RCL: 70.99 (+3.13)
Allergan targets liver disease drugs with Tobira acquisition
By The Associated Press - AP - Tue Sep 20, 5:45PM CDT
Botox-maker Allergan is bulking up its drug pipeline with two acquisitions announced Tuesday, both of which target liver disease.
AGN: 243.43 (+5.02), TBRA: 39.50 (+0.42)
Tobira, Royal Caribbean and Marriott rise; Ascena dives
AP - Tue Sep 20, 4:49PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
AGN: 243.43 (+5.02), GE: 30.04 (+0.19), LEN: 43.60 (+0.15), RCL: 70.99 (+3.13), PIR: 4.26 (+0.16), ASNA: 5.91 (+0.34), LEN.B: 34.80 (+0.20), MAR: 69.75 (-0.39), TBRA: 39.50 (+0.42)
Business Highlights
By The Associated Press - AP - Tue Sep 20, 4:17PM CDT
___
AGN: 243.43 (+5.02), FDX: 173.66 (-0.20), MON: 104.20 (-0.16), MYL: 42.59 (+0.68), M: 36.26 (+0.25), WFC: 45.72 (-0.11), TBRA: 39.50 (+0.42)
Why Did Tobira Therapeutics (TBRA) Stock Skyrocket 720% Today?
Madeleine Johnson - Zacks Investment Research - Tue Sep 20, 3:49PM CDT
On Tuesday, shares of Tobira Therapeutics Inc. (TBRA) skyrocketed, up over 720% in late-afternoon trading after the company announced it would be acquired by Allergan (AGN) in a deal worth up to $1.7 billion.
AGN: 243.43 (+5.02), TBRA: 39.50 (+0.42)
Akarna Therapeutics Ltd acquired by Allergan plc
BusinessWire - Tue Sep 20, 3:23PM CDT
Akarna Therapeutics Ltd., a privately held biopharmaceutical company, announced today that it has been acquired by Allergan plc. Allergan obtains rights to AKN-083, Akarna's lead product candidate for the potential treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases.
AGN: 243.43 (+5.02)
Allergan Acquires Akarna Therapeutics Adding to its Strong Development Program and Commitment to Innovation in NASH
PR Newswire - Tue Sep 20, 3:15PM CDT
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the Company has acquired Akarna Therapeutics Ltd., a privately held biopharmaceutical company focused on developing novel small molecule therapeutics that target inflammatory and fibrotic diseases, for an up-front payment of $50 million, subject to certain adjustments, as well as potential clinical, regulatory and commercial milestone payments related to its lead development compound, AKN-083. In addition to AKN-083, the acquisition also includes a portfolio of additional development-stage FXR compounds.
AGN: 243.43 (+5.02), TBRA: 39.50 (+0.42)
Watch for Allergan to Potentially Rebound After Falling 2.40% Yesterday
Comtex SmarTrend(R) - Tue Sep 20, 11:45AM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $237.85 to a high of $243.94. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $243.72 on volume of 3.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 243.43 (+5.02)
TOBIRA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
BusinessWire - Tue Sep 20, 10:43AM CDT
Rigrodsky & Long, P.A.:
AGN: 243.43 (+5.02), TBRA: 39.50 (+0.42)
